(Rac)-Sograzepide

Cat. No.: HY-U00360

CAS No.: 168161-71-5

Molecular Formula: $C_{28}H_{30}N_6O_3$

Molecular Weight: 498.58

Target: Cholecystokinin Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (250.71 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0057 mL	10.0285 mL	20.0570 mL
	5 mM	0.4011 mL	2.0057 mL	4.0114 mL
	10 mM	0.2006 mL	1.0028 mL	2.0057 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.08 mg/mL (4.17 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.17 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.08 mg/mL (4.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(Rac)-Sograzepide is an antagonist of cholecystokinin B (CCK-B) receptor, and has the potential of reducing the secretion of gastric acid.

IC_{50} & Target

CCK-B receptor[1]

In Vitro

(Rac)-Sograzepide is an antagonist of CCK-B receptor, and has the potential of reducing the secretion of gastric acid[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hamish Ryder, et al. Benzodiazepin derivatives useful as cck-receptor antagonists. WO 1993016999 A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA